GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Spero Therapeutics Inc (NAS:SPRO) » Definitions » Price-to-Tangible-Book

Spero Therapeutics (Spero Therapeutics) Price-to-Tangible-Book : 0.71 (As of Apr. 25, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Spero Therapeutics Price-to-Tangible-Book?

As of today (2024-04-25), Spero Therapeutics's share price is $1.43. Spero Therapeutics's Tangible Book per Share of Dec. 2023 for the quarter that ended in Dec. 2023 was $2.02. Hence, Spero Therapeutics's Price to Tangible Book Ratio of today is 0.71.

The historical rank and industry rank for Spero Therapeutics's Price-to-Tangible-Book or its related term are showing as below:

SPRO' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.7   Med: 2   Max: 5.88
Current: 0.71

During the past 9 years, Spero Therapeutics's highest Price to Tangible Book Ratio was 5.88. The lowest was 0.70. And the median was 2.00.

SPRO's Price-to-Tangible-Book is ranked better than
89.18% of 1220 companies
in the Biotechnology industry
Industry Median: 2.67 vs SPRO: 0.71

A closely related ratio is called PB Ratio. As of today, Spero Therapeutics's share price is $1.43. Spero Therapeutics's Book Value per Sharefor the quarter that ended in Dec. 2023 was $2.02. Hence, Spero Therapeutics's P/B Ratio of today is 0.71.


Spero Therapeutics Price-to-Tangible-Book Historical Data

The historical data trend for Spero Therapeutics's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Spero Therapeutics Price-to-Tangible-Book Chart

Spero Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Tangible-Book
Get a 7-Day Free Trial Premium Member Only 2.48 4.30 5.88 1.19 0.73

Spero Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Tangible-Book Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.19 1.18 1.39 1.19 0.73

Competitive Comparison of Spero Therapeutics's Price-to-Tangible-Book

For the Biotechnology subindustry, Spero Therapeutics's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Spero Therapeutics's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Spero Therapeutics's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Spero Therapeutics's Price-to-Tangible-Book falls into.



Spero Therapeutics Price-to-Tangible-Book Calculation

Spero Therapeutics's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book=Share Price/Tangible Book per Share (Q: Dec. 2023 )
=1.43/2.017
=0.71

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.


Spero Therapeutics Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Spero Therapeutics's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.


Spero Therapeutics (Spero Therapeutics) Business Description

Traded in Other Exchanges
Address
675 Massachusetts Avenue, 14th Floor, Cambridge, MA, USA, 02139
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
Executives
Kamal Hamed officer: Chief Medical Officer 675 MASSACHUSETTS AVENUE, 14TH FLOOR, CAMBRIDGE MA 02139
Sath Shukla officer: Chief Financial Officer C/O ZIOPHARM ONCOLOGY, INC., ONE FIRST AVENUE, PARRIS BUILDING #34, BOSTON MA 02129
Timothy Keutzer officer: Chief Development Officer C/O SPERO THERAPEUTICS, INC., 675 MASSACHUSETTS AVENUE, 14TH FLOOR, CAMBRIDGE MA 02139
Ankit Mahadevia director, officer: See Remarks C/O SPERO THERAPEUTICS, INC., 675 MASSACHUSETTS AVE., 14TH FLOOR, CAMBRIDGE MA 02139
Tamara L Joseph officer: Chief Legal Officer 32 GARRISON STREET, APT 50-103, BOSTON MA 02116
Aquilo Capital Management, Llc 10 percent owner ONE LETTERMAN DRIVE, SUITE D4900, BUILDING D, SAN FRANCISCO CA 94129
Kathleen Tregoning director C/O CEREVEL THERAPEUTICS HOLDINGS, INC., 131 DARTMOUTH STREET SUITE 502, BOSTON MA 02116
Cristina Larkin officer: Chief Operating Officer C/O SPERO THERAPEUTICS, INC., 675 MASSACHUSETTS AVENUE, 14TH FLOOR, CAMBRIDGE MA 02139
Aquilo Capital, L.p. 10 percent owner ONE LETTERMAN DRIVE, SUITE D4900, BUILDING D, THE PRESIDIO, SAN FRANCISCO CA 94129
Scott Thomas Jackson director 303B COLLEGE ROAD EAST, PRINCETON NJ 08540
Stephen J. Dipalma officer: Interim CFO C/O SPERO THERAPEUTICS, INC., 675 MASSACHUSETTS AVENUE, 14TH FLOOR, CAMBRIDGE MA 02139
Cynthia Smith director 508 WRANGLER DRIVE, SUITE 100, COPPELL TX 75019
Pottage John C Jr director ACHILLION PHARMACEUTICALS, 300 GEORGE STREET, NEW HAVEN CT 06511
Plc Glaxosmithkline 10 percent owner 980 GREAT WEST ROAD, BRENTFORD MIDDLESEX X0 TW8 9GS
Joel Sendek officer: Chief Financial Officer C/O SPERO THERAPEUTICS, INC., 675 MASSACHUSETTS AVENUE, 14TH FLOOR, CAMBRIDGE MA 02139